Rinri Therapeutics Limited

Rinri Therapeutics Limited is dedicated to pioneering regenerative cell therapies aimed at treating hearing loss through innovative biological approaches, targeting the underlying causes of auditory impairment. Rinri Therapeutics Limited focuses on the development of regenerative therapies for hearing loss, established in 2018 in Sheffield, UK. The company was founded by Marcelo Rivolta and has pursued strategic deals in the healthcare sector, achieving a total of 3 completed deals as of May 2021. The latest funding, a GRANT amounting to GBP 3.

2 million led by Innovate UK, has contributed to a total capital raised of GBP 10. 0 million. Rinri Therapeutics Ltd. specializes in innovative regenerative cell therapies aimed at addressing hearing loss.

Their core product offerings focus on advanced cellular treatments designed to restore auditory function by targeting the underlying biological mechanisms of hearing impairment. The primary end use case is the potential restoration of hearing for individuals experiencing sensorineural hearing loss, which affects a significant segment of the population. These therapies are developed through cutting-edge research and are intended to serve a diverse customer base, including healthcare providers, specialized clinics, and patients in need of novel treatment options. Rinri Therapeutics operates in various geographical markets, including Europe and North America, ensuring access to these breakthrough therapies for a broad audience suffering from hearing loss.

Rinri Therapeutics generates revenue through direct partnerships with healthcare facilities and specialized clinics that incorporate their regenerative therapies into their treatment offerings. The company’s transaction structure typically involves B2B agreements where healthcare providers pay for the therapies administered to patients. These transactions may include fixed fees for specific treatment protocols or service agreements that encompass ongoing support and training for medical professionals. As the company focuses on high-value treatments for hearing loss, revenue is driven by the uptake of their flagship therapies within clinical practices, with specific pricing details established based on contractual agreements with partner institutions.

In May 2021, Rinri Therapeutics Limited secured GBP 3. 2 million of grant funding led by Innovate UK, aimed at advancing the development of their stem cell therapy for reversing sensorineural hearing loss. The company plans to leverage this funding to enhance their product offerings and expand their market reach. Future plans include launching new therapies focused on hearing restoration and targeting expansion into additional markets in Europe and North America by 2023.